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ABSTRACT
Susceptibilities to 11 antimicrobial agents were determined by Etest for 93 Nocardia isolates from clinical
specimens and 15 type strains belonging to different Nocardia spp. All isolates were susceptible to
trimethoprim-sulphamethoxazole, amikacin and linezolid, but susceptibilities of the various Nocardia
spp. to b-lactams, aminoglycosides, ciprofloxacin and clarithromycin varied markedly. Overall, there
was a good correlation between the drug resistance patterns and the species identification established by
conventional phenotypic tests and 16S rDNA sequencing. Among the different species encountered,
Nocardia farcinica and Nocardia brasiliensis displayed the most multiresistant profiles, with resistance to
imipenem occurring mainly among isolates of N. brasiliensis and Nocardia abscessus. The species
variability in susceptibility profiles and the numerous recent taxonomic changes means that in-vitro
susceptibility tests may be a complementary tool for the identification of Nocardia isolates from human
clinical specimens. Further studies on a larger number of species from more diverse geographical
sources, including species that are found less commonly among clinical isolates, are required to validate
and extend the results.
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INTRODUCTION
Nocardia spp. are isolated with increasing fre-
quency from clinical specimens, and especially
from immunocompromised patients [1]. The
taxonomy of the genus Nocardia has been
revised extensively during recent years, and a
number of unnamed taxons have been delinea-
ted [2,3]. Within the genus, Nocardia asteroides
has usually been considered to be the most
frequent species isolated from clinical specimens
[4–9]. However, this species has been shown to
be heterogeneous (termed the N. asteroides com-
plex) and has now been divided into several
different species [2,3,10], and new species isola-
ted from humans have also been described [11–
13]. Identification of Nocardia isolates to the
species level is difficult by means of routine
phenotypic tests, but a simple identification
scheme, based on a panel of nine conventional
phenotypic and enzymatic tests, has been devel-
oped and validated for the rapid identification
of the most common Nocardia spp. found in
human clinical specimens [14]. Molecular tests
using PCR and sequencing of the 16S rDNA
gene have been advocated for the accurate
identification of Nocardia isolates to the species
level [2,10], and in-vitro susceptibility patterns
have been shown to differ among Nocardia spp.,
and to allow the separation of the N. asteroides
complex into six distinct groups [15].
Few in-vitro studies of the use of antimicrobial
susceptibility profiles to identify the various
Nocardia spp. have been carried out since the latest
taxonomic changes [2,3]. The aim of the present
studywas to assess the drug susceptibility patterns
ofNocardia spp. found in a large number of clinical
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specimens against a panel of antimicrobial agents
by means of the Etest.
MATERIALS AND METHODS
Microorganisms
Ninety-three Nocardia isolates from human clinical specimens
in Belgium were investigated, of which 83 were isolated
between 1990 and 2005, and ten were isolated before 1990. The
isolates were collected by 21 laboratories in various parts of
Belgium. All theNocardia isolates were included in the study in
order to avoid any bias in selection. Only one isolate per
patient was considered. Identification to the species level was
by conventional biochemical tests (resistance to lysozyme,
production of urease, hydrolysis of gelatin, degradation of
casein, tyrosine, xanthine and hypoxanthine), acid production
from rhamnose, citrate alkalinisation, enzymatic activities and
growth at 45C. In addition, the entire 16S rDNA gene of each
isolate was sequenced and aligned with library sequences of
type strains in the GenBank database [14].
Reference type strains of 15 different Nocardia spp. isolated
from human clinical specimens were also tested for their
susceptibilities: N. asteroides (NCTC 11293T), N. abscessus (DSM
44432T), N. africana (DSM 44491T), N. asiatica (DSM 44668T), N.
brasiliensis (NCTC 11294T), N. carnea (DSM 43397T), N. cyriac-
igeorgica (DSM 44484T), N. farcinica (DSM 43665T), N. niigatensis
(DSM 44670T), N. nova (DSM 43207T), N. paucivorans (DSM
44386T), N. pseudobrasiliensis (DSM 44290T), N. otitidiscaviarum
(NCT1934T), N. transvalensis (DSM 43405T) and N. veterana
(DSM 44445T). Staphylococcus aureus ATCC 25923, Enterococcus
faecalis ATCC 29212 and Escherichia coli ATCC 35218 (for
amoxycillin-clavulanate only) were used as quality controls to
monitor the antimicrobial susceptibility tests.
Inoculum preparation
The Nocardia isolates were subcultured twice on sheep blood
agar to ensure purity. A large amount of growth was scraped
from the second sheep blood agar plate, inoculated into 20 mL
Mueller-Hinton (MH) broth, and incubated at 35C for 24–48 h
on a rotary shaker. Sterile glass beads (3 mm in diameter) were
added to each flask to minimise the formation of clumps of
nocardial growth during cultivation. In order to prevent the
formation of irregular clumps, tubes were vortexed periodic-
ally at high speed for 2 min to achieve a uniform suspension,
and vortexing was repeated before determination of ODs. The
final inoculum was adjusted to an OD equivalent to a 1.0
MacFarland standard with a densitometer (Densimat; bio-
Me´rieux, Marcy-l’Etoile, France).
Antimicrobial susceptibility testing
MICs were determined by Etest (AB Biodisk, Solna, Sweden)
on 150-mm MH agar plates inoculated by confluent swabbing
using a Retro C80 automatic inoculating device (AB Biodisk).
A maximum of five Etest strips were applied to each MH agar
plate with the Simplex C76 Etest instrument (AB Biodisk).
Plates were incubated at 35C in ambient air and interpreted in
accordance with the guidelines provided by the manufacturer.
Results were recorded after 48 h (or after 72 h if growth was
insufficient after 48 h).
Antimicrobial agents
The following antimicrobial agents were tested (concentration
ranges in mg ⁄L): ampicillin (0.016–256), amoxycillin + clavul-
anic acid 2 : 1 (0.016–256), piperacillin+tazobactam
(0.016–256 + 4), ceftriaxone (0.016–256), imipenem (0.002–32),
ciprofloxacin (0.002–32), tobramycin (0.016–256), amikacin
(0.016–256), clarithromycin (0.016–256), linezolid (0.016–256),
trimethoprim + sulphamethoxazole 1 : 19 (0.002–32) and
minocycline (0.016–256).
b-Lactamase testing
b-Lactamase determination was by the nitrocefin disk method
(Cefinase; Becton Dickinson, Erembodegem, Belgium). Colour
change readings were taken for up to 1 h and were recorded as
positive or negative. Isolates with negative test results were
subcultured on MH agar plates on which amoxycillin +
clavulanate disks were placed. After adequate growth, colon-
ies growing closest to the zone of inhibition were retested for
b-lactamase activity by the nitrocefin disk method as described
above (to detect amoxycillin + clavulanate-induced b-lacta-
mase).
Interpretation of susceptibility results
Results were interpreted as susceptible, intermediately-resist-
ant or resistant according to the breakpoints recommended by
the CLSI (NCCLS) for Nocardia and other aerobic actinomyc-
etes [16], except for amoxycillin and piperacillin + tazobactam,
for which CLSI interpretative criteria for Enterobacteriaceae
were used to establish tentative breakpoint values [17].
RESULTS
The species distribution (n) of the clinical isolates
was as follows: N. farcinica (41), N. nova (20),
N. cyriacigeorgica (13),N. brasiliensis (6),N. abscessus
(6), N. paucivorans (2), N. asiatica (1), N. carnea (1),
N. elegans (1), N. niigatensis (1) and N. veterana (1).
Thirty-nine isolates were from the respiratory
tract, 18 from superficial abscesses or wounds,
ten from blood, six from brain abscesses and one
from cerebrospinal fluid. Nineteen isolates were
of unknown origin.
All except six isolates (two N. abscessus, two
N. nova, one N. cyriacigeorgica, one N. paucivorans)
produced adequate growth on unsupplemented
MHA and yielded ODs of ‡ 1.0 McFarland in
£ 48 h at 35C. Coarse clumping growth was
common, but the addition of glass beads and
periodic vortexing helped to break-up clumps
and pellicles. For the six isolates mentioned
above, the incubation period was extended to
72 h because of insufficient growth.
Growth inhibition ellipses were uniform and
well-delineated, and the points of intersectionwith
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the Etest strips were easy to determine. The MIC
results for the 86 isolates belonging to the most
common species are summarised in Table 1. All 93
Nocardia isolates from clinical specimens were
susceptible to amikacin, trimethoprim + sulpha-
methoxazole and linezolid. Trimethoprim +
sulphamethoxazole displayed the highest intrinsic
activity on the basis of the MIC50 value









Nocardia farcinica (n = 41)
Amoxycillin 0.38–128 16 48 9.7
Amoxycillin + clavulanate 0.5–4 2 3 100
Piperacillin + tazobactam 24- > 256 > 256 > 256 0
Ceftriaxone 0.38- > 256 96 > 256 22.0
Imipenem 0.047–3 0.75 1.5 100
Ciprofloxacin 0.047- > 32 0.75 8 53.7
Clarithromycin 1.5- > 256 16 32 4.9
Minocycline 0.047–4 2 4 12.1
Linezolid 0.047–6 1.5 3 100
TMP + SMX 0.016–2 0.064 0.75 100
Amikacin 0.38–2 0.75 1 100
Tobramycin 2–32 16 24 7.3
Nocardia nova (n = 20)
Amoxycillin 0.032–1.5 0.125 0.5 100
Amoxycillin + clavulanate 1- > 256 8 > 256 50
Piperacillin + tazobactam 0.023- > 256 > 256 > 256 30
Ceftriaxone 0.032- > 256 2 32 70
Imipenem 0.002–1 0.032 0.064 100
Ciprofloxacin 8- > 32 > 32 > 32 0
Clarithromycin < 0.016–0.064 0.016 0.032 100
Minocycline 0.25–6 1.5 3 35
Linezolid 0.25–3 1 2 100
TMP + SMX 0.064–0.75 0.25 0.75 100
Amikacin 0.016–0.25 0.064 0.25 100
Tobramycin 1–16 4 8 60
Nocardia cyriacigeorgica (n = 13)
Amoxycillin 2- > 256 8 > 256 61.5
Amoxycillin + clavulanate 4–128 6 12 76.9
Piperacillin + tazobactam > 256 > 256 > 256 0
Ceftriaxone 0.5–4 1 3 100
Imipenem 0.094–1.5 0.38 1.5 100
Ciprofloxacin > 32 > 32 > 32 0
Clarithromycin 4- > 256 24 > 256 0
Minocycline 0.5–4 1.5 3 30.7
Linezolid 0.25–2 1 1.5 100
TMP + SMX 0.016–0.25 0.064 0.19 100
Amikacin 0.19–1 0.38 0.75 100
Tobramycin < 0.016–0.19 0.032 0.064 100
Nocardia abscessus (n = 6)
Amoxycillin 0.016–3 0.38 3 100
Amoxycillin + clavulanate 0.016–0.38 0.064 0.38 100
Piperacillin + tazobactam 1- > 256 8 > 256 50
Ceftriaxone 0.125–1.5 0.5 1.5 100
Imipenem 0.094- > 32 2 > 32 50
Ciprofloxacin 1.5- > 32 32 > 32 0
Clarithromycin 1.5–8 2 8 66.7
Minocycline 0.016–1 0.032 1 100
Linezolid 0.125–1.5 0.5 1.5 100
TMP + SMX 0.004–0.094 0.032 0.125 100
Amikacin 0.064–0.19 0.125 0.19 100
Tobramycin 0.016–0.5 0.094 0.5 100
Nocardia brasiliensis (n = 6)
Amoxycillin 0.5–48 12 48 33.3
Amoxycillin + clavulanate 0.25–4 0.75 4 100
Piperacillin + tazobactam 6- > 256 > 256 > 256 16.6
Ceftriaxone 1- > 256 6 > 256 50
Imipenem 8- > 32 > 32 > 32 0
Ciprofloxacin 1.5- > 32 8 > 32 0
Clarithromycin 4- > 256 12 > 256 0
Minocycline 0.38–2 0.75 2 83.3
Linezolid 0.25–1.5 0.25 1.5 100
TMP + SMX 0.004–0.047 0.032 0.047 100
Amikacin 0.094–1 0.5 1 100
Tobramycin < 0.016–0.064 0.032 0.064 100
aSusceptibility results for seven clinical isolates (N. paucivorans, 2; N. carnea, 1; N. asiatica, 1; N. elegans, 1; N. niigatensis, 1; N. veterana, 1) are not included in the table (see Results
in the text).
bAccording to CLSI guidelines [16,17].
TMP + SMX, trimethoprim + sulphamethoxazole.
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(0.064 mg ⁄L), followed by amikacin (0.38 mg ⁄L)
and linezolid (1 mg ⁄L). No resistance to minocy-
cline was observed, but 70% of isolates had MICs
in the intermediate susceptibility category (MIC50,
2 mg ⁄L). The activity of b-lactams was variable,
with 89% of isolates being susceptible to imipe-
nem, 84% to amoxycillin + clavulanate, 55% to
ceftriaxone, 50% to amoxycillin (MIC £ 8 mg ⁄L),
and 9% to piperacillin + tazobactam (MIC £ 16
mg ⁄L). Other antimicrobial agents with varying
and species-dependant activity were tobramycin
(52% susceptible), clarithromycin (32% suscepti-
ble) and ciprofloxacin (31% susceptible).
b-Lactam agents
All theNocardia isolates, including the 15 reference
strains, showed b-lactamase activity by the nitro-
cefin disk test. Among the clinical isolates, 73
showed a positive reaction within 5–10 min, and
14 showed a gradually positive reaction over a
period of 1 h. For six isolates of N. nova, the
nitrocefin test was initially negative, but became
positive after re-testing colonies subcultured on
MHA with amoxycillin + clavulanate.
Despite displaying b-lactamase activity, all
N. nova isolates were susceptible to amoxycillin,
while c.50% of the isolates belonging to this species
were either intermediately-resistant or resistant
to amoxicillin + clavulanate (Tables 1 and 2). The
inhibitory activity of amoxycillin was 4->100-fold
superior to that of amoxycillin + clavulanate for
each individual isolate ofN. nova. Conversely, over
90% of all N. farcinica isolates were resistant to
amoxycillin, and all were uniformly susceptible to
amoxycillin + clavulanate. Likewise, amoxycillin +
clavulanate appeared to be significantly more
active in vitro than amoxycillin alone against
N. brasiliensis isolates (MIC50 0.75 and 16 mg ⁄L,
respectively). Against N. cyriacigeorgica and
N. abscessus, amoxycillin and amoxycillin + clavul-
anate had equal activity, althoughN. cyriacigeorgica
was usually less susceptible (MIC50 8 mg ⁄L for
both amoxycillin and amoxycillin + clavulanate)
thanN. abscessus (MIC50 0.38 mg ⁄L for amoxycillin
and 0.064 mg ⁄L for amoxycillin + clavulanate).
Piperacillin + tazobactam did not display signifi-
cant activity against most of the Nocardia spp.
tested. Resistance to ceftriaxone was observed
primarily in N. farcinica and, to a lesser extent, in
N. brasiliensis and N. nova (Table 2). Resistance to
imipenem was observed with all N. brasiliensis
isolates, three of six N. abscessus isolates, and the
single clinical isolate of N. niigatensis.
Among the less common species, two isolates
ofNocardia paucivorans and one isolate ofN. carnea
were susceptible to all b-lactams tested, except
piperacillin + tazobactam. One isolate of
N. veterana had a resistance profile very similar
to that of N. nova (amoxycillin MIC 2 mg ⁄L,
amoxycillin + clavulanate MIC 8 mg ⁄L, ceftriax-
one MIC > 256 mg ⁄L). One isolate of N. asiatica
was equally sensitive to amoxycillin and amoxy-
cillin + clavulanate (MIC 2 mg ⁄L for both
compounds), and was also sensitive to ceftriaxone
(MIC 0.38 mg ⁄L) and imipenem (MIC 0.25 mg ⁄L).
The antibiotic susceptibilities of the 15 different
Nocardia type strains are shown in Table 3. The
susceptibility profiles to b-lactams were highly
diverse for the different species. High-level resist-
ance to b-lactams, including ceftriaxone and
imipenem, was found in reference strains of
N. brasiliensis, N. otitidiscaviarum and N. niigaten-
sis. The reference strain of N. pseudobrasiliensis also
displayed elevated MICs of amoxycillin and
ceftriaxone but, unlike N. brasiliensis, remained
susceptible to imipenem.
Fluoroquinolones
Resistance to ciprofloxacin was found in several
Nocardia spp. including N. nova, N. cyriacigeorgica,
N. abscessus and N. brasiliensis, while a variable
susceptibility pattern was found in N. farcinica
Table 2. Frequency of susceptibility of various Nocardia spp. to selected antimicrobial agents
Species Amoxycillin
Amoxycillin +
clavulanate Ceftriaxone Imipenem Ciprofloxacin Clarithromycin Tobramycin
Nocardia farcinica (n = 41) 10 100 22 100 54 5 7b
Nocardia nova (n = 20) 100 50a 70 100 0 100 60b
Nocardia cyriacigeorgica (n = 13) 62 83 100 100 0 0 100
Nocardia abscessus (n = 6) 100 100 100 50 0 67 100
Nocardia brasiliensis (n = 6) 33 100 50 0 0 0 100
aHigher MICs of amoxycillin + clavulanate than of amoxycillin alone for all N. nova isolates.
bHigher MICs of tobramycin for susceptible isolates of N. farcinica (MIC 2–4 mg ⁄L) and for N. nova (MIC 1–4 mg ⁄L) in comparison with all other Nocardia spp.
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(Tables 1 and 2). Among the less common species,
N. paucivorans (two isolates), N. carnea (one iso-
late), and the type strains of these two species,
were susceptible to ciprofloxacin.
Macrolides
Resistance to clarithromycin was observed in all
isolates of N. cyriacigeorgica and N. brasiliensis, and
in > 95% of N. farcinica isolates. Two strains of
N. asiatica (one clinical isolate and one type strain)
also displayed high-level resistance to clarithro-
mycin (MIC > 256 mg ⁄L). Conversely, N. nova
isolates were uniformly susceptible to clarithro-
mycin (MIC50 0.016 mg ⁄L; MIC90 0.032 mg ⁄L);
two-thirds of the N. abscessus isolates were sus-
ceptible, but with MIC values close to the break-
point limit (MIC50 2 mg ⁄L).
Aminoglycosides
All isolates of Nocardia spp. were susceptible to
amikacin. Resistance to tobramycin was observed
in > 90% of all N. farcinica isolates, and in 40% of
the N. nova isolates. All susceptible isolates of N.
nova and N. farcinica had elevated tobramycin
MICs that were close to the breakpoint (MICs 1–
4 mg ⁄L). In contrast, most other species were
highly susceptible to tobramycin (Tables 1 and 3),
with the exception of N. veterana and N. africana,
two species that are closely related taxonomically
to N. nova. Furthermore, the reference strain of N.
transvalensis, a species related closely to N. astero-
ides sensu stricto type IV, was also highly resistant
to tobramycin (MIC > 256 mg ⁄L), and had a
moderate level of susceptibility to amikacin
(MIC 8 mg ⁄L) (Table 3).
DISCUSSION
Antimicrobial susceptibility testing of Nocardia
isolates is recommended as a guide to therapy for
cases of severe and disseminated infection, for
refractory cases, or for patients who are intolerant
to treatment with sulphonamides [1]. Testing may
also be considered when relatively resistant spe-
cies, or a newly described species, has been
isolated, but laboratory results should always be
interpreted with caution because of the paucity of
studies that correlate in-vitro data with clinical
outcome. Performance and interpretation of tests
for antimicrobial susceptibility of Nocardia spp.
are problematic because of the slow growth of
these organisms. Furthermore, the frequent occur-
rence of clumps and aggregates makes the pre-
paration of a uniform homogeneous inoculum
difficult.
The CLSI have approved a standard method for
susceptibility testing and interpretation by broth
microdilution in cation-supplemented MH [16].
Other tests include disk-diffusion, agar dilution,
Etests and the Bactec radiometric growth index
method. Several studies have shown rates of
inter- and intra-laboratory agreement and repro-
ducibility of > 90% between these different meth-
ods and the approved broth microdilution
standard method [17–19]. For example, a study
testing 52 clinical isolates of Nocardia belonging to
five different species by Etest and microbroth
dilution MICs revealed 89% agreement for all
drugs within ± 1 log2 dilution [18]. Using CLSI
interpretative criteria, there was 96.2% agreement
between Etests and microbroth dilution. In an-
other study, Ambaye et al. [19] found 96.6%
agreement between Etests and the consensus
Table 3. MICs (mg ⁄L) of culture collection reference strains of 15 Nocardia spp. to seven antimicrobial agents
Species (collection type ⁄number) Amoxycillin
Amoxycillin +
clavulanate Ceftriaxone Imipenem Ciprofloxacin Clarithromycin Tobramycin
Nocardia farcinica (DSM 43665T) 4 1 8 0.19 0.38 4 24
Nocardia nova (DSM 43207T) 0.25 4 6 0.032 > 32 < 0.016 8
Nocardia cyriacigeorgica (DSM 44484T) 3 6 1.5 0.5 > 32 16 0.064
Nocardia brasiliensis (NCTC 11294T) > 256 0.5 > 256 > 32 32 > 256 < 0.016
Nocardia abscessus (DSM 44432T) 0.25 0.25 0.38 1 12 3 0.25
Nocardia paucivorans (DSM 44836 T) 0.25 2 0.5 0.064 0.012 > 256 < 0.016
Nocardia carnea (DSM 43397T) 4 0.25 0.25 0.125 0.094 8 0.016
Nocardia asiatica (DSM 44668T) 12 256 0.75 0.19 > 32 256 0.75
Nocardia niigatensis (DSM 44670T) > 256 128 32 > 32 1 0.032 0.094
Nocardia veterana (DSM 44445T) 0.25 2 4 0.023 > 32 0.023 16
Nocardia africana (DSM44491T) 4 32 32 0.125 > 32 0.016 48
Nocardia otitidiscaviarum (NCTC 1934T) > 256 64 > 256 > 32 1 > 256 1
Nocardia pseudobrasiliensis (DSM 44290T) > 256 3 256 2 0.25 0.016 1
Nocardia transvalensis (DSM 43405T) > 256 32 4 0.5 0.25 0.5 > 256
Nocardia asteroides (NCTC 11293T) 4 16 2 0.38 4 2 < 0.016
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susceptibility results of five different testing
methods, with no major errors and only four
very major errors (1.8% of the total tests)
observed with Etests, all of which occurred with
amoxycillin + clavulanate or ceftriaxone. Like-
wise, Tomlin et al. [20] reported > 90% agreement
between Etests and disk-diffusion results for 36
clinical isolates of N. asteroides using CLSI break-
points for Enterobacteriaceae. Of the different
methods, the Etest appears to be the most attract-
ive method as it provides quantitative informa-
tion (MIC values) that may be useful for tailoring
therapy, and because it is highly flexible and
suitable for the routine clinical laboratory.
There are few data in the literature concerning
the antimicrobial susceptibility patterns of Nocar-
dia isolates [15,18–22], and these early reports only
included a small number of Nocardia isolates and
suffered from a failure to identify isolates accu-
rately to the species level. The present study
determined the susceptibility patterns of 93 clin-
ical isolates of Nocardia spp., all of which were
identified by phenotypic and molecular tests [14].
As the isolates originated from a large number of
laboratories and from different clinical sources,
the distribution and prevalence of the various
Nocardia spp. may be considered to be represen-
tative for Belgium.
N. farcinica, the predominant species in this
study (45% of all clinical isolates) showed a rather
typical multidrug resistance pattern, character-
ised by resistance to amoxycillin, ceftriaxone,
clarithromycin and tobramycin, with susceptibil-
ity to amoxycillin + clavulanate and imipenem, in
line with previous reports for this species [15,21].
N. nova, which accounted for c.20% of the
clinical isolates, had a distinctive susceptibility
pattern, characterised by susceptibility to amoxy-
cillin and clarithromycin, but with resistance to
amoxicillin + clavulanate in c.50% of the isolates,
caused by the fact that N. nova isolates have an
inducible membrane-bound penicillinase which is
induced by clavulanic acid, but not by amoxycil-
lin alone [22]. Indeed, positive b-lactamase activ-
ity was observed following induction by
clavulanic acid in only six of the 20 N. nova
isolates. A similar observation has been reported
previously [19].
N. cyriacigeorgica accounts for > 60% of nocar-
dia infections in humans in the USA [1,2,], but
ranked in only third position in the present study.
All isolates of N. cyriacigeorgica were characterised
by susceptibility to ceftriaxone and imipenem,
and resistance to ciprofloxacin and clarithromy-
cin. Variable results were observed with amoxy-
cillin and amoxycillin + clavulanic acid. The
susceptibility profile observed for the N. cyriaci-
georgica isolates matched exactly with the type VI
drug pattern of N. asteroides reported previously
[15]. Thus, clinical isolates previously classified
generically as N. asteroides with a type VI drug
susceptibility pattern may have corresponded to
N. cyriacigeorgica.
Among other species, some of the N. abscessus
isolates had susceptibility patterns that were very
similar to that reported previously for N. asteroides
sensu stricto type I [15]. The results for the
N. brasiliensis isolates mostly agreed with those
of a recent study from Mexico [23]. However, few
conclusions can be reached concerning the drug
resistance profiles of the less common species of
Nocardia since they were represented by only
a few isolates. Some of these species (e.g.,
N. paucivorans and N. carnea) have been reported
only rarely as pathogens in humans [1,10], while
others (N. asiatica, N. niigatensis) were only des-
cribed quite recently [11,12].
Wide variations in the resistance profiles to
b-lactams were observed in both clinical isolates
and in type strains. Several distinct b-lactamases,
inducible or expressed constitutively, have been
characterised in various Nocardia spp. including
N. asteroides sensu stricto [24] andN. farcinica [25,26],
and it is likely that these account, at least in part, for
the variations in resistance to b-lactams among
species.b-Lactamases ofNocardia have been shown
to differ in their spectrum and kinetics towards
different substrates. All characterised Nocardia b-
lactamases are class A b-lactamases, which behave
as penicillinases and confer high levels of resist-
ance to amoxycillin, piperacillin and cephalothin
[24–26]. Their hydrolytic activity is inhibited par-
tially by clavulanic acid, but almost not at all
by sulbactam and tazobactam, which probably
explains the lack of activity of piperacillin +
tazobactam against most Nocardia isolates. Resist-
ance to ceftriaxone and to imipenem does not seem
to be mediated by b-lactamases, but rather by
decreased affinities of penicillin-binding proteins
for these molecules [26].
The present study also confirmed the excellent
in-vitro activity of trimethoprim + sulphameth-
oxazole, amikacin and linezolid against all Nocar-
dia spp. [18,19,22,23,27]. Although no resistance to
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minocycline was observed, the MIC values fell in
the decreased susceptibility category for most
isolates, as has been reported previously [15,20].
In conclusion, the present study detected large
variations in the antimicrobial susceptibility pro-
files of different Nocardia spp. and the existence of
homogeneous drug resistance patterns among
several species included formerly in the N. astero-
ides complex [15,19,20]. Susceptibility testing of
selected antimicrobial agents by Etest could be
useful, both for therapeutic purposes and as a
simple complementary tool for identification of
several of the Nocardia spp. associated frequently
with human infections. However, > 90% of all
clinical Nocardia isolates encountered in this sur-
vey belonged to only five species; the small
number of strains for some species and the
limited geographical area in which the study
was performed do not permit extrapolation of the
results to other areas. Further studies with a
larger panel of isolates from more diverse geo-
graphical regions, including other Nocardia spp.
occurring less commonly in humans, are required
to validate and extend the results.
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